Ivabradine shown to be ineffective for certain heart patients
A new study published in the European Journal of Heart Failure has shown that the heart medication ivabradine may not be beneficial for all heart patients, reports Yahoo News.
In a randomized clinical trial, patients with heart failure and preserved ejection fraction did not respond well to ivabradine, meaning the drug did not reduce their heart rate.
"Potential explanations for failure are lack of sufficient power since recruitment was interrupted due to difficulties in finding patients, and the idea that heart rate lowering is beneficial in this condition could be wrong if patients have extensive fibrosis and thus no reserve in stroke volume. In that case, changes in cardiac output are totally dependent of heart rate, and reducing heart rate in this context could be detrimental," said lead author Michel Komajda.
To read the full story, follow the link below:
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.